1. Thase ME. Are SNRIs more effective than SSRIs? Medscape. Available at: http://www.medscape.com/viewarticle/578077. Accessed July 28, 2008.
2. Lamb E. Top 200 prescription drugs of 2008. Pharmacy Times. May 2009. Available at: http://www.pharmacytimes.com/issue/pharmacy/2009/2009-05/RxFocusTop200Drugs-0509. Accessed August 17, 2009.
3. Cipriani A, Funkawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373:746-758.
4. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-260.
5. Hetrick SE, Merry SN, McKenzie J, et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Sys Rev. 2007(3);CD004851.-
6. Agency for Healthcare Research and Quality. Newer class of antidepressants similar in effectiveness, but side effects differ. January 24, 2007. Available at: http://www.ahrq.gov/news/press/pr2007/antideppr.htm. Accessed August 20, 2009.
7. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol. 1999;19:467-489.
8. Dording CM, Mischoulon D, Peterson TJ, et al. The pharmacologic management of selective serotonin reuptake inhibitor-induced side effects: a survey of psychiatrists. Ann Clin Psychiatr. 2002;14:143-147.
9. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc. 2001;76:511-527.
10. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders–I. Basic pharmacology. J Psychopharmacol. 1998;12(suppl B):S5-S20.
11. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy. Arch Gen Psychiatry. 2008;65:795-803.
12. Boyer E, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120.
13. Prozac [package insert]. Indianapolis: Eli Lilly and Company; 2008.
14. Celexa [package insert]. St. Louis: Forest Pharmaceuticals, Inc.; 2008.
15. Lexapro [package insert]. St. Louis: Forest Pharmaceuticals, Inc.; 2008.
16. Paxil CR [package insert]. Research Triangle Park, NC: Glaxo SmithKline; 2008.
17. Paxil [package insert]. Research Triangle Park, NC: GlaxoSmith-Kline; 2008.
18. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics. 2005;46:464-494.
19. Baldwin D, Montgomery SA, Nil R, et al. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol. 2007;10:73-84.
20. Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. Prim Care Companion J Clin Psychiatry. 2001;3:168-174.
21. van Geffen EC, Hugtenburg JG, Heerdink ER, et al. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol. 2005;61:303-307.
22. Alder J, Fink N, Bitzer J, et al. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med. 2007;20:189-209.
23. ACOG Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists No. 92, April 2008. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111:1001-1020.
24. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499-507.
25. US Health and Human Services. Pregnancy and medicines: frequently asked questions. Available at: http://womenshealth.gov/FAQ/pregnancy-medicines.cfm. Last updated May 1, 2007. Accessed December 17, 2009.
26. Food and Drug Administration. Public Health Advisory Paroxetine. Available at: www.drugs.com/news/fda-public-health-advisory-paroxetine-1646.html. Accessed December 17, 2009.
27. FDA proposes new rule to provide updated information on the use of prescription drugs and biological products during pregnancy and breastfeeding. May 28, 2008. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116902.htm. Accessed December 17, 2009.
28. Chambers CD, Hernandez-Diaz S, Van Marter LS, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579-587.
29. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173-176.
30. Food and Drug Administration. Relationship between psychotropic drugs and pediatric suicidality. August 16, 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf. Accessed August 20, 2009.
31. Food and Drug Administration. FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. May 2, 2007. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108905.htm. Accessed August 20, 2009.
32. Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry. 2008;165:42-50.
33. Hammerness PG, Vivas FM, Geller DA. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. J Pediatr. 2006;148:158-165.
